220 related articles for article (PubMed ID: 34093580)
1. Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques.
Pollara J; Tay MZ; Edwards RW; Goodman D; Crowley AR; Edwards RJ; Easterhoff D; Conley HE; Hoxie T; Gurley T; Jones C; Machiele E; Tuyishime M; Donahue E; Jha S; Spreng RL; Hope TJ; Wiehe K; He MM; Moody MA; Saunders KO; Ackerman ME; Ferrari G; Tomaras GD
Front Immunol; 2021; 12():678511. PubMed ID: 34093580
[TBL] [Abstract][Full Text] [Related]
2. Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.
Pollara J; Jones DI; Huffman T; Edwards RW; Dennis M; Li SH; Jha S; Goodman D; Kumar A; LaBranche CC; Montefiori DC; Fouda GG; Hope TJ; Tomaras GD; Staats HF; Ferrari G; Permar SR
J Virol; 2019 May; 93(10):. PubMed ID: 30842326
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
4. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
[TBL] [Abstract][Full Text] [Related]
6. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis.
Spencer DA; Goldberg BS; Pandey S; Ordonez T; Dufloo J; Barnette P; Sutton WF; Henderson H; Agnor R; Gao L; Bruel T; Schwartz O; Haigwood NL; Ackerman ME; Hessell AJ
Nat Commun; 2022 Feb; 13(1):662. PubMed ID: 35115533
[TBL] [Abstract][Full Text] [Related]
7. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
8. Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies.
Chu TH; Crowley AR; Backes I; Chang C; Tay M; Broge T; Tuyishime M; Ferrari G; Seaman MS; Richardson SI; Tomaras GD; Alter G; Leib D; Ackerman ME
PLoS Pathog; 2020 Feb; 16(2):e1008083. PubMed ID: 32092122
[TBL] [Abstract][Full Text] [Related]
9. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.
Brown EP; Dowell KG; Boesch AW; Normandin E; Mahan AE; Chu T; Barouch DH; Bailey-Kellogg C; Alter G; Ackerman ME
J Immunol Methods; 2017 Apr; 443():33-44. PubMed ID: 28163018
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC.
Worley MJ; Fei K; Lopez-Denman AJ; Kelleher AD; Kent SJ; Chung AW
J Immunol Methods; 2018 Jun; 457():41-52. PubMed ID: 29605231
[TBL] [Abstract][Full Text] [Related]
11. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
Moldt B; Schultz N; Dunlop DC; Alpert MD; Harvey JD; Evans DT; Poignard P; Hessell AJ; Burton DR
J Virol; 2011 Oct; 85(20):10572-81. PubMed ID: 21849450
[TBL] [Abstract][Full Text] [Related]
12. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.
Asokan M; Dias J; Liu C; Maximova A; Ernste K; Pegu A; McKee K; Shi W; Chen X; Almasri C; Promsote W; Ambrozak DR; Gama L; Hu J; Douek DC; Todd JP; Lifson JD; Fourati S; Sekaly RP; Crowley AR; Ackerman ME; Ko SH; Kilam D; Boritz EA; Liao LE; Best K; Perelson AS; Mascola JR; Koup RA
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18754-18763. PubMed ID: 32690707
[TBL] [Abstract][Full Text] [Related]
13. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.
Sholukh AM; Watkins JD; Vyas HK; Gupta S; Lakhashe SK; Thorat S; Zhou M; Hemashettar G; Bachler BC; Forthal DN; Villinger F; Sattentau QJ; Weiss RA; Agatic G; Corti D; Lanzavecchia A; Heeney JL; Ruprecht RM
Vaccine; 2015 Apr; 33(17):2086-95. PubMed ID: 25769884
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among humans and rhesus macaques.
Tuyishime M; Spreng RL; Hueber B; Nohara J; Goodman D; Chan C; Barfield R; Beck WE; Jha S; Asdell S; Wiehe K; He MM; Easterhoff D; Conley HE; Hoxie T; Gurley T; Jones C; Adhikary ND; Villinger F; Thomas R; Denny TN; Moody MA; Tomaras GD; Pollara J; Reeves RK; Ferrari G
Front Immunol; 2023; 14():1260377. PubMed ID: 38124734
[TBL] [Abstract][Full Text] [Related]
15. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
[TBL] [Abstract][Full Text] [Related]
16. Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.
Nakane T; Nomura T; Shi S; Nakamura M; Naruse TK; Kimura A; Matano T; Yamamoto H
PLoS One; 2013; 8(9):e73453. PubMed ID: 24039947
[TBL] [Abstract][Full Text] [Related]
17. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody.
Richardson SI; Lambson BE; Crowley AR; Bashirova A; Scheepers C; Garrett N; Abdool Karim S; Mkhize NN; Carrington M; Ackerman ME; Moore PL; Morris L
PLoS Pathog; 2019 Dec; 15(12):e1008064. PubMed ID: 31841557
[TBL] [Abstract][Full Text] [Related]
18. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
19. Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.
Vargas-Inchaustegui DA; Robert-Guroff M
Curr HIV Res; 2013 Jul; 11(5):407-20. PubMed ID: 24191937
[TBL] [Abstract][Full Text] [Related]
20. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.
Ko SY; Pegu A; Rudicell RS; Yang ZY; Joyce MG; Chen X; Wang K; Bao S; Kraemer TD; Rath T; Zeng M; Schmidt SD; Todd JP; Penzak SR; Saunders KO; Nason MC; Haase AT; Rao SS; Blumberg RS; Mascola JR; Nabel GJ
Nature; 2014 Oct; 514(7524):642-5. PubMed ID: 25119033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
